Evidence map›Paper›PMID 25320245›Full record

ArticleBlood2014

Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1.

Tomohiro Umezu, Hiroko Tadokoro, Kenko Azuma, Seiichiro Yoshizawa, Kazuma Ohyashiki, Junko H Ohyashiki

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 368 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
368citing papers in PubMed, 1 pooled it
14.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

368 citing papers in PubMed, 1 synthesis or guideline pooled it, 592 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Research on exosomes in cancer multidrug resistance and clinical translation.Extracellular vesicles and circulating nucleic acids · 2026
    Review
  18. Review
  19. Review
  20. Article

308 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Tomohiro UmezuDepartment of Molecular Science, Tokyo Medical University, Tokyo, Japan; Institute of Medical Science, Tokyo Medical University, Tokyo, Japan.
Hiroko TadokoroDepartment of Pharmaceutical Health Care and Sciences, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan;
Kenko AzumaDepartment of Hematology and Institute of Medical Science, Tokyo Medical University, Tokyo, Japan.
Seiichiro YoshizawaDepartment of Hematology and.
Kazuma OhyashikiDepartment of Molecular Science, Tokyo Medical University, Tokyo, Japan; Department of Hematology and.
Junko H OhyashikiInstitute of Medical Science, Tokyo Medical University, Tokyo, Japan.
Tokyo Medical University · JPTokyo University of Pharmacy and Life Sciences · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Exosomes are small endosome-derived vesicles containing a wide range of functional proteins, mRNA, and miRNA. Exosomal miRNA from cancer cells helps modulate the microenvironment. In multiple myeloma (MM), the massive proliferation of malignant plasma cells causes hypoxia. To date, the majority of in vitro hypoxia studies of cancer cells have used acute hypoxic exposure (3-24 hours). Thus, we attempted to clarify the role of MM-derived exosomes in hypoxic bone marrow by using MM cells grown continuously in vitro under chronic hypoxia (hypoxia-resistant MM [HR-MM] cells). The HR-MM cells produced more exosomes than the parental cells under normoxia or acute hypoxia conditions, and miR-135b was significantly upregulated in exosomes from HR-MM cells. Exosomal miR-135b directly suppressed its target factor-inhibiting hypoxia-inducible factor 1 (FIH-1) in endothelial cells. Finally, exosomal miR-135b from HR-MM cells enhanced endothelial tube formation under hypoxia via the HIF-FIH signaling pathway. This in vitro HR myeloma cell model will be useful for investigating MM cell-endothelial cell interactions under hypoxic conditions, which may mimic the in vivo bone marrow microenvironment. Although tumor angiogenesis is regulated by various factors, exosomal miR-135b may be a target for controlling MM angiogenesis.

Indexed as

3' Untranslated RegionsBlood VesselsBlotting, WesternCell HypoxiaCell Line, TumorCells, CulturedExosomesGene Expression ProfilingGene Expression Regulation, NeoplasticGene Knockdown TechniquesHumansHuman Umbilical Vein Endothelial CellsLuciferasesMicroRNAsMicroscopy, Electron, TransmissionMixed Function Oxygenases3' Untranslated RegionsHIF1AN protein, humanLuciferasesMicroRNAsMIRN135 microRNA, humanMixed Function OxygenasesRepressor Proteins

Identifiers

PMID25320245
PMCPMC4263983
OpenAlexW2001149149

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.